Major drugmaker loses $27 billion in market value after failed trial

Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.

Summary aggregated from MarketWatch's public RSS feed. The full reporting belongs to MarketWatch — please read it on their site.